Virion Therapeutics, LLC
PrivateLast Round
Private Placement
Aug 21, 2024
Est. Valuation
$40.91M
Total Funding Raised
$5M
Company Overview
Virion Therapeutics, LLC is a biotechnology company that develops novel, adaptable, and accessible CD8+ T cell-based immunotherapies for cancer and chronic infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Virion Therapeutics, LLC Comparables
Compare Virion Therapeutics, LLC with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AusperBio | 82% | |
| nChroma Bio | 81% | |
| Arbutus Biopharma Corp | 79% |
For institutional investors. Book with your work email.
Virion Therapeutics, LLC Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Aug 21, 2024 | ||||
| Joint Venture | Oct 11, 2023 | ||||
| Series A | Sep 26, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Virion Therapeutics, LLC Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Keiretsu Forum | Series A |
| Crimson Peak | Series A |
| Robin Hood Ventures | Series A |
| Alliance of Angels | Series A |
| Life Science Angels | Series A |
| MABA | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 22, 2026
Presented study results at the CROI 2026 conference.
- Feb 22, 2026
VRON-0200 showed broad and sustained anti-HBV immunity in chronic HBV patients.
For institutional investors. Book with your work email.
Virion Therapeutics, LLC Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Virion Therapeutics, LLC's valuation, stock price, and market status.
Is Virion Therapeutics, LLC a public or private company?
Virion Therapeutics, LLC is a private company.
What is the current stock price of Virion Therapeutics, LLC?
Virion Therapeutics, LLC is a private company, so its shares have no public market price. Caplight tracks Virion Therapeutics, LLC's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Virion Therapeutics, LLC worth (valuation)?
Virion Therapeutics, LLC's valuation is estimated at $40.9M based on funding round data.
Can I buy Virion Therapeutics, LLC stock?
Virion Therapeutics, LLC shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Virion Therapeutics, LLC's last funding round?
Virion Therapeutics, LLC's most recent funding round was Private Placement on August 21, 2024.
Who are the main investors in Virion Therapeutics, LLC?
Key investors in Virion Therapeutics, LLC include Robin Hood Ventures.
Will Virion Therapeutics, LLC IPO soon?
No public IPO plans have been announced for Virion Therapeutics, LLC.
How can I track Virion Therapeutics, LLC secondary market activity?
Caplight tracks bids, offers, and trades in Virion Therapeutics, LLC's shares on secondary markets.